Aktueller Stand der Impfung gegen SARS-CoV-2

On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty®, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna®, Moderna, Cambridge, MA, USA) followed on 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Iking-Konert, Christof, Specker, Christof, Krüger, Klaus, Schulze-Koops, Hendrik, Aries, Peer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Hot Topics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852047/
https://www.ncbi.nlm.nih.gov/pubmed/33528655
http://dx.doi.org/10.1007/s00393-021-00966-9
Descripción
Sumario:On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty®, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna®, Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.

Ejemplares similares